BACKGROUND: The discovery of antidepressant medications has revolutionized the treatment of depression and other psychiatric illnesses. The coming of the selective serotonin (5-HT) reuptake inhibitors (SSRIs) marked a new era in the treatment of depression. These therapies frequently fall short of getting the patient to remission. Agents with a dual action have subsequently been developed which inhibit the reuptake of both 5-HT and NE, getting more patients to remission. Physical symptoms are associated with depression, preventing the patient from obtaining complete recovery. This article provides an overview of the pharmacology, efficacy, and techniques for the clinical use of duloxetine, a dual reuptake inhibitor, which has recently become available. METHODS: The English literature has been reviewed including both controlled and uncontrolled studies. RESULTS: Duloxetine is a dual reuptake inhibitor with actions on serotonin as well as norepinephrine. It has been shown to have efficacy in treating depressive symptoms including those with painful physical symptoms. Common side effects include nausea, insomnia, and dizziness. CONCLUSIONS: The article has been written with clinicians as the target audience, the data suggesting it can be used as a first line agent.
BACKGROUND: The discovery of antidepressant medications has revolutionized the treatment of depression and other psychiatric illnesses. The coming of the selective serotonin (5-HT) reuptake inhibitors (SSRIs) marked a new era in the treatment of depression. These therapies frequently fall short of getting the patient to remission. Agents with a dual action have subsequently been developed which inhibit the reuptake of both 5-HT and NE, getting more patients to remission. Physical symptoms are associated with depression, preventing the patient from obtaining complete recovery. This article provides an overview of the pharmacology, efficacy, and techniques for the clinical use of duloxetine, a dual reuptake inhibitor, which has recently become available. METHODS: The English literature has been reviewed including both controlled and uncontrolled studies. RESULTS:Duloxetine is a dual reuptake inhibitor with actions on serotonin as well as norepinephrine. It has been shown to have efficacy in treating depressive symptoms including those with painful physical symptoms. Common side effects include nausea, insomnia, and dizziness. CONCLUSIONS: The article has been written with clinicians as the target audience, the data suggesting it can be used as a first line agent.
Authors: Elena Di Nasso; Alberto Chiesa; Alessandro Serretti; Diana De Ronchi; Claudio Mencacci Journal: Clin Drug Investig Date: 2011 Impact factor: 2.859
Authors: Marina López-Solà; Jesus Pujol; Rosa Hernández-Ribas; Ben J Harrison; Oren Contreras-Rodríguez; Carles Soriano-Mas; Joan Deus; Héctor Ortiz; José M Menchón; Julio Vallejo; Narcís Cardoner Journal: Neuropsychopharmacology Date: 2010-07-28 Impact factor: 7.853
Authors: A S Dayananda; Jerry P Jasinski; James A Golen; H S Yathirajan; B Narayana Journal: Acta Crystallogr Sect E Struct Rep Online Date: 2011-08-06